Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460278 | 0.98 | MEN1 (0.61) | MEN1KMT2AKDM4EL3MBTL1L3MBTL3 | |
| SCHEMBL1461514 | 0.86 | MEN1 (0.57) | MEN1KMT2AKDM4EGAAOPRM1 | |
| SCHEMBL1460325 | 0.86 | MEN1 (0.57) | MEN1KMT2AKDM4EGAAOPRM1 | |
| SCHEMBL1461910 | 0.86 | GAA (0.73) | MEN1KMT2AKDM4EGAAOPRM1 | |
| SCHEMBL1462399 | 0.86 | KDM4E (0.57) | MEN1KMT2AKDM4EL3MBTL1GAA | |
| SCHEMBL1461382 | 0.86 | GMNN (0.55) | MEN1KMT2AKDM4EL3MBTL1L3MBTL3 | |
| SCHEMBL1460371 | 0.86 | HRH3 (0.53) | MEN1KMT2AKDM4EL3MBTL1GAA | |
| SCHEMBL1460306 | 0.84 | GAA (0.69) | MEN1KMT2AKDM4EGAAOPRM1 | |
| SCHEMBL12573567 | 0.84 | GAA (0.69) | MEN1KMT2AKDM4EGAAOPRM1 | |
| SCHEMBL8223804 | 0.84 | GAA (0.69) | MEN1KMT2AKDM4EGAAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2475643-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011026959-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | MEN1 1411/4885KMT2A 4088/4885KDM4E 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.